Abstract: This disclosure demonstrated that cyanobacteria bioengineered with cyanobacterial lipid-biosynthetic-promoting genes could produce large quantities of SDA, as well as rarely observed ETA. Importantly, the biosynthesized omega-3 fatty acids, such as SDA and ETA, are found conjugated to more bioavailable glycolipids, including MGDG and DGDG. Novel compositions include MGDG, DGDG, SQDG, and PG molecular species that contain the following n-3 PUFAs and n-3 LC-PUFAs at both sn-1 and sn-2 positions: 18:3/18:4, 18:3/20:4, 18:3/20:5, 18:4/18:4, 18:4/20:4, 18:4/20:5. These compositions are not found in nature and result from the engineering of cyanobacteria; and can serve as highly bioavailable, cost-effective anti-inflammatory compounds. These compositions, therefore, have strong anti-inflammatory properties with the likely capacity to block activities of cyclooxygenases, lipoxygenases, and cytochrome P450s that metabolize PUFAs and LC-PUFAs to pro-inflammatory mediators.

Abstract: This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

Abstract: This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier.This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).